Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Poster P-061

Is D2 lymphadenectomy essential for cytology-positive gastric cancer? A propensity score-matched analysis

Introduction

Gastrectomy is generally performed for gastric cancer with positive peritoneal lavage cytology (CY1) but no other distant metastases. However, the appropriate extent of lymphadenectomy is uncertain. We retrospectively compared the overall survival after standard and limited lymphadenectomy.

Methods

We reviewed the medical records in four institutions from 2007 to 2018. Eighty-two consecutive patients with CY1 but no other distant metastases who underwent gastrectomy were analyzed. D2 or D2+ lymphadenectomy was performed for 48 patients and <D2 lymphadenectomy for 34 patients. Overall survival was compared using the Kaplan-Meier method and log-rank test. To reduce selection bias, we conducted a propensity score matching analysis. The patients’ propensity scores were estimated using a logistic regression model based on the following variables; age, performance status score, Onodera’s prognostic nutritional index (PNI), clinical nodal status, extent of gastrectomy, macroscopic tumor type, and postoperative chemotherapy.

Results

The full cohort analyses showed that patients were younger, had better PNIes, had more advanced cN, and a higher number received postoperative chemotherapy in the ≥D2 group than in the <D2 group. The median overall survival times were 23.0 months after ≥D2 lymphadenectomy and 13.1 months after <D2 lymphadenectomy (p = 0.010). Twenty-five pairs of patients were generated via propensity score matching. The clinical characteristics of the two groups were well matched. The median overall survival time was 23.2 months after D2 lymphadenectomy and 13.7 months after <D2 lymphadenectomy (p = 0.029).

Conclusion

The prognoses of CY1 gastric cancer patients were better after standard lymphadenectomy than after limited lymphadenectomy.

Publisher
Oxford University Press
Source Journal
Annals of Oncology
E ISSN 1569-8041 ISSN 0923-7534

Advertisement

Advertisement

Advertisement

Advertisement